Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
0.3620
Dollar change
-0.0080
Percentage change
-2.16
%
Index- P/E- EPS (ttm)-8.53 Insider Own4.70% Shs Outstand8.43M Perf Week3.02%
Market Cap3.05M Forward P/E- EPS next Y- Insider Trans311.81% Shs Float8.03M Perf Month38.75%
Income-18.98M PEG- EPS next Q- Inst Own3.98% Short Float1.29% Perf Quarter-71.72%
Sales0.00M P/S- EPS this Y- Inst Trans1.09% Short Ratio0.26 Perf Half Y-64.51%
Book/sh-0.41 P/B- EPS next Y- ROA-317.24% Short Interest0.10M Perf Year-63.43%
Cash/sh0.11 P/C3.35 EPS next 5Y- ROE-570.59% 52W Range0.23 - 4.40 Perf YTD-71.50%
Dividend Est.- P/FCF- EPS past 5Y-94.80% ROI- 52W High-91.77% Beta1.09
Dividend TTM- Quick Ratio0.51 Sales past 5Y0.00% Gross Margin- 52W Low58.08% ATR (14)0.05
Dividend Ex-Date- Current Ratio0.51 EPS Y/Y TTM17.92% Oper. Margin0.00% RSI (14)45.30 Volatility8.65% 14.29%
Employees5 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom3.00 Target Price30.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q57.75% Payout- Rel Volume0.45 Prev Close0.37
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsNov 16 AMC Avg Volume404.20K Price0.36
SMA20-4.72% SMA50-1.48% SMA200-74.49% Trades Volume180,889 Change-2.16%
Date Action Analyst Rating Change Price Target Change
Dec-28-20Downgrade Ladenburg Thalmann Buy → Neutral
Aug-24-20Initiated Ladenburg Thalmann Buy $11
Jan-29-24 09:00PM
Jan-18-24 08:45AM
Jan-17-24 08:45AM
Dec-18-23 08:35AM
Dec-06-23 09:00AM
09:05AM Loading…
Nov-22-23 09:05AM
Nov-16-23 10:00AM
Nov-15-23 08:00AM
Oct-19-23 09:05AM
Oct-18-23 10:00AM
Oct-16-23 09:00AM
Oct-11-23 08:45AM
Sep-07-23 08:45AM
Sep-05-23 08:45AM
Aug-14-23 08:35AM
07:35AM Loading…
07:35AM
Aug-03-23 08:15AM
08:00AM
Jul-27-23 09:05AM
Jul-05-23 08:45AM
Jun-14-23 09:05AM
May-25-23 09:05AM
May-15-23 08:35AM
May-08-23 08:45AM
May-03-23 08:45AM
Apr-27-23 08:45AM
Apr-17-23 06:54AM
Apr-10-23 08:45AM
Apr-06-23 09:05AM
Apr-03-23 08:05AM
09:05AM Loading…
Mar-29-23 09:05AM
Mar-13-23 07:05AM
Mar-09-23 09:05AM
Feb-07-23 08:45AM
Jan-12-23 08:45AM
Jan-11-23 01:00PM
Jan-05-23 09:05AM
Jan-03-23 02:28PM
12:00PM
Dec-08-22 09:08AM
Dec-05-22 08:05AM
Nov-30-22 10:00PM
Nov-28-22 04:53PM
Nov-15-22 01:09PM
Nov-14-22 04:05PM
Nov-02-22 08:45AM
Oct-10-22 09:00AM
Oct-07-22 08:00AM
Sep-28-22 09:05AM
Sep-23-22 09:00AM
Sep-07-22 08:45AM
Aug-15-22 08:05AM
Jul-25-22 08:05AM
Jun-23-22 08:35AM
Jun-08-22 08:35AM
May-24-22 07:00AM
May-19-22 03:57PM
May-18-22 08:35AM
May-16-22 08:05AM
Apr-28-22 08:35AM
Apr-13-22 10:45AM
Apr-12-22 08:35AM
Apr-06-22 08:35AM
Apr-05-22 08:35AM
Mar-23-22 08:35AM
Mar-09-22 09:20AM
Mar-03-22 08:35AM
Feb-01-22 07:30AM
Jan-20-22 09:40AM
08:45AM
Jan-12-22 10:35AM
Jan-10-22 05:00PM
Jan-07-22 08:05AM
Jan-06-22 07:00AM
Dec-31-21 01:50PM
Dec-21-21 10:00AM
Dec-02-21 08:35AM
Nov-16-21 08:00AM
Nov-04-21 02:30PM
Oct-11-21 08:00AM
Sep-30-21 12:25PM
08:05AM
Aug-15-21 03:41AM
Aug-13-21 08:05AM
Jul-12-21 07:30AM
Jul-01-21 09:05AM
Jun-29-21 10:19AM
08:35AM
Jun-28-21 07:30AM
Jun-17-21 09:05AM
May-19-21 08:05AM
May-14-21 09:05AM
May-13-21 03:23AM
May-11-21 08:35AM
Mar-15-21 09:00AM
Mar-04-21 09:00AM
Feb-25-21 09:05AM
Feb-24-21 07:30AM
Feb-18-21 01:45PM
09:05AM
CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Climaco John MChief Executive OfficerFeb 01 '24Buy0.30166,66650,000215,676Feb 06 10:27 AM
Downs ChristopherChief Financial OfficerFeb 01 '24Buy0.3066,66620,000103,438Feb 06 10:27 AM
Evans Carl AnthonyDirectorFeb 01 '24Buy0.3033,33310,00033,458Feb 06 10:27 AM
Gumulka JerzyDirectorFeb 01 '24Buy0.3033,33310,00043,006Feb 06 10:28 AM
Downs ChristopherChief Financial OfficerAug 22 '23Buy1.2727,00034,17736,772Aug 23 08:00 AM
Climaco John MChief Executive OfficerAug 16 '23Buy1.802,7504,94449,010Aug 16 04:01 PM
Gumulka JerzyDirectorApr 19 '23Buy1.702,5004,2509,673Apr 21 07:58 AM
Downs ChristopherChief Financial OfficerApr 17 '23Buy3.203,1009,9209,251Apr 18 08:00 AM
Climaco John MChief Executive OfficerApr 12 '23Buy0.6915,00010,40845,010Apr 14 04:20 PM
Gumulka JerzyDirectorApr 10 '23Buy0.747,1735,3087,173Apr 17 08:17 AM